AIS Healthcare Celebrates National Nurses Month

AIS Healthcare, a leading provider of targeted drug delivery (TDD) and infusion care solutions, is proud to recognize May as National Nurses Month. This month and throughout the year, AIS Healthcare celebrates the dedication of nurses who devote themselves to protecting and enhancing the well-being of those in need of care.

Nurses play a critical role in healthcare delivery in the United States and across the world. Thanks to advancements in medical science and technology, their role has expanded, often serving as a first point of contact for patients. AIS Healthcare nurses hold certifications in specialty infusion care and undergo advanced and ongoing clinical training, allowing them to provide patients with the best possible care. AIS Healthcare’s Advanced Nursing Solutions team is led by experienced professionals who understand what it takes to advance quality of life and improve health outcomes for patients afflicted with chronic pain and complex medical conditions.

“National Nurses Month gives us an opportunity to celebrate the pivotal role of nurses and their commitment to improving patient lives,” said Simon Castellanos, CEO of AIS Healthcare. “AIS Healthcare’s nurses deliver comprehensive care services and build strong connections and relationships that enable patients to better thrive in their communities and homes. We are grateful for their selfless dedication today and every day.”

AIS Healthcare’s Advanced Infusion Care (AIC) and TDD divisions utilize innovative healthcare solutions to manage patients’ needs. Collaboration between physicians and the AIS nursing team ensures the efficient delivery of patient-specific services and enhances the care experience for patients managing complex conditions.

Nurses change patient lives for the better. During National Nurses Month and throughout the year, AIS Healthcare encourages individuals, communities, and organizations to show their appreciation for nurses. To learn more about AIS Healthcare’s leading nursing program, visit here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version